Proton pump inhibitors and dementia: physiopathological mechanisms and clinical consequences

Resultado de la investigación: Contribución a RevistaArtículo de revisión

2 Citas (Scopus)
13 Downloads (Pure)

Resumen

Alzheimer’s disease (AD) is the most common type of dementia, mainly encompassing cognitive decline in subjects aged ≥ 65 years. Further, AD is characterized by selective synaptic and neuronal degeneration, vascular dysfunction, and two histopathological features: extracellular amyloid plaques composed of amyloid-beta peptide (Aβ), and neurofibrillary tangles formed by hyperphosphorylated tau protein. Dementia and AD are chronic neurodegenerative conditions with a complex physiopathology involving both genetic and environmental factors. Recent clinical studies have shown that proton pump inhibitors (PPIs) are associated with risk of dementia, including AD. However, a recent case-control study reported decreased risk of dementia. PPIs are a widely indicated class of drugs for gastric acid-related disorders, although most older adult users are not treated for the correct indication. Although neurological side effects secondary to PPIs are rare, several preclinical reports indicate that PPIs might increase Aβ levels, interact with tau protein, and affect the neuronal microenvironment through several mechanisms. Considering the controversy between PPI use and dementia risk, as well as both cognitive and neuroprotective effects, the aim of this review is to examine the relationship between PPI use and brain effects from a neurobiological and clinical perspective.
Idioma originalEnglish (US)
Número de artículo5257285
PublicaciónNeural Plasticity
EstadoPublished - mar 21 2018

Huella dactilar

Proton Pump Inhibitors
Dementia
Alzheimer Disease
tau Proteins
Neurofibrillary Tangles
Amyloid beta-Peptides
Gastric Acid
Amyloid Plaques
Neuroprotective Agents
Blood Vessels
Case-Control Studies
Brain
Pharmaceutical Preparations

Citar esto

@article{9aa8ff3658fe48368b98ab654cfe8c50,
title = "Proton pump inhibitors and dementia: physiopathological mechanisms and clinical consequences",
abstract = "Alzheimer’s disease (AD) is the most common type of dementia, mainly encompassing cognitive decline in subjects aged ≥ 65 years. Further, AD is characterized by selective synaptic and neuronal degeneration, vascular dysfunction, and two histopathological features: extracellular amyloid plaques composed of amyloid-beta peptide (Aβ), and neurofibrillary tangles formed by hyperphosphorylated tau protein. Dementia and AD are chronic neurodegenerative conditions with a complex physiopathology involving both genetic and environmental factors. Recent clinical studies have shown that proton pump inhibitors (PPIs) are associated with risk of dementia, including AD. However, a recent case-control study reported decreased risk of dementia. PPIs are a widely indicated class of drugs for gastric acid-related disorders, although most older adult users are not treated for the correct indication. Although neurological side effects secondary to PPIs are rare, several preclinical reports indicate that PPIs might increase Aβ levels, interact with tau protein, and affect the neuronal microenvironment through several mechanisms. Considering the controversy between PPI use and dementia risk, as well as both cognitive and neuroprotective effects, the aim of this review is to examine the relationship between PPI use and brain effects from a neurobiological and clinical perspective.",
author = "{Nava Mesa}, {Mauricio Orlando} and {Amador Munoz}, {Diana Patricia} and {Calderon Ospina}, {Carlos Alberto} and Gloria Ortiz-Guerrero and Daniel Lopez-Fuentes",
year = "2018",
month = "3",
day = "21",
language = "English (US)",
journal = "Neural Plasticity",
issn = "2090-5904",
publisher = "Hindawi Publishing Corporation",

}

Proton pump inhibitors and dementia: physiopathological mechanisms and clinical consequences. / Nava Mesa, Mauricio Orlando; Amador Munoz, Diana Patricia; Calderon Ospina, Carlos Alberto; Ortiz-Guerrero, Gloria; Lopez-Fuentes, Daniel.

En: Neural Plasticity, 21.03.2018.

Resultado de la investigación: Contribución a RevistaArtículo de revisión

TY - JOUR

T1 - Proton pump inhibitors and dementia: physiopathological mechanisms and clinical consequences

AU - Nava Mesa, Mauricio Orlando

AU - Amador Munoz, Diana Patricia

AU - Calderon Ospina, Carlos Alberto

AU - Ortiz-Guerrero, Gloria

AU - Lopez-Fuentes, Daniel

PY - 2018/3/21

Y1 - 2018/3/21

N2 - Alzheimer’s disease (AD) is the most common type of dementia, mainly encompassing cognitive decline in subjects aged ≥ 65 years. Further, AD is characterized by selective synaptic and neuronal degeneration, vascular dysfunction, and two histopathological features: extracellular amyloid plaques composed of amyloid-beta peptide (Aβ), and neurofibrillary tangles formed by hyperphosphorylated tau protein. Dementia and AD are chronic neurodegenerative conditions with a complex physiopathology involving both genetic and environmental factors. Recent clinical studies have shown that proton pump inhibitors (PPIs) are associated with risk of dementia, including AD. However, a recent case-control study reported decreased risk of dementia. PPIs are a widely indicated class of drugs for gastric acid-related disorders, although most older adult users are not treated for the correct indication. Although neurological side effects secondary to PPIs are rare, several preclinical reports indicate that PPIs might increase Aβ levels, interact with tau protein, and affect the neuronal microenvironment through several mechanisms. Considering the controversy between PPI use and dementia risk, as well as both cognitive and neuroprotective effects, the aim of this review is to examine the relationship between PPI use and brain effects from a neurobiological and clinical perspective.

AB - Alzheimer’s disease (AD) is the most common type of dementia, mainly encompassing cognitive decline in subjects aged ≥ 65 years. Further, AD is characterized by selective synaptic and neuronal degeneration, vascular dysfunction, and two histopathological features: extracellular amyloid plaques composed of amyloid-beta peptide (Aβ), and neurofibrillary tangles formed by hyperphosphorylated tau protein. Dementia and AD are chronic neurodegenerative conditions with a complex physiopathology involving both genetic and environmental factors. Recent clinical studies have shown that proton pump inhibitors (PPIs) are associated with risk of dementia, including AD. However, a recent case-control study reported decreased risk of dementia. PPIs are a widely indicated class of drugs for gastric acid-related disorders, although most older adult users are not treated for the correct indication. Although neurological side effects secondary to PPIs are rare, several preclinical reports indicate that PPIs might increase Aβ levels, interact with tau protein, and affect the neuronal microenvironment through several mechanisms. Considering the controversy between PPI use and dementia risk, as well as both cognitive and neuroprotective effects, the aim of this review is to examine the relationship between PPI use and brain effects from a neurobiological and clinical perspective.

M3 - Review article

JO - Neural Plasticity

JF - Neural Plasticity

SN - 2090-5904

M1 - 5257285

ER -